Neuphoria Therapeutics Inc. (NEUP) scores 48 out of 100 on boothcheck's 11-model valuation framework. Verdict: Poor The estimated fair value is 7.44, representing a 68% margin of safety. Quantitative score: 47/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.